Deals
Teva Climbs Above $50 Per Share as Buyouts Lift Earnings Outlook
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd., the world’s largest maker of generic drugs, rallied above $50 per share for the first time since 2011 as speculation mounted that consolidation among generic drug companies will bolster earnings.
Shares of the Petach-Tikva, Israel-based company advanced 2.4 percent to $50.48 at 1:59 p.m. in New York, the highest since June 2011. They rose 13 percent in February, heading for the best monthly performance since January 2007.